Drs Jacob Sands and Shawn Regis discuss the risks and benefits of lung cancer screening.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969532). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

National Lung Screening Trial https://www.cancer.gov/types/lung/research/nlst

Lung Cancer: Screening, 1996 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening-1996

NELSON Lung Cancer Screening Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266562/

Early Lung Cancer Detection in High Risk Individuals (MILD) https://clinicaltrials.gov/ct2/show/NCT02837809

Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task Force https://www.ncbi.nlm.nih.gov/books/NBK568573/

Appendix A Table 5. Recommendations for Lung Cancer Screening With LDCT https://www.ncbi.nlm.nih.gov/books/NBK568579/table/appa.tab5/?report=objectonly

ALA Press Release https://www.lung.org/media/press-releases/new-sbts-psa-1

Lung CT Screening Reporting & Data System (Lung-RADS) https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads

Outcomes of Positive and Suspicious Findings in Clinical CT Lung Cancer Screening and the Road Ahead https://pubmed.ncbi.nlm.nih.gov/34818144/

Lung Cancer Incidence and Mortality With Extended Follow-up in the National Lung Screening Trial https://www.jto.org/article/S1556-0864(19)30473-3/fulltext

Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation https://www.jto.org/article/S1556-0864(20)30993-X/fulltext

American Thoracic Society and American Lung Association Implementation Guide for Lung Cancer Screening https://www.lungcancerscreeningguide.org/

Rescue Lung Society https://rescuelung.org/

Lung Cancer Screening Resources https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/saved-by-the-scan/resources

Go2 Foundation for Lung Cancer https://go2foundation.org/

Drs Jacob Sands and Pasi Jänne discuss the effectiveness of biomarkers and targeted therapies for lung cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969533). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

Resources

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma https://www.nejm.org/doi/full/10.1056/nejmoa0810699

The Value of Next-Generation Sequencing in Patients With Non-Small Cell Lung Cancer https://www.medscape.org/viewarticle/975903

ctDNA Shows Promise for Assessing Lung Cancer Treatment Response https://www.medscape.com/viewarticle/965587

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2005653

Structure-Based Classification Predicts Drug Response in EGFR-Mutant NSCLC https://www.nature.com/articles/s41586-021-03898-1

Targeting Uncommon EGFR Mutations in Advanced NSCLC https://reference.medscape.com/recap/952720

Afatinib Prescribing Information https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Gilotrif/Gilotrif.pdf?DMW_FORMAT=pdf

Amivantamab Prescribing Information https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf

Mobocertinib Prescribing Information https://content.takeda.com/?contenttype=pi&product=exkivity&language=eng&country=usa&documentnumber=1

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa1713137

Real-World Incidence and Impact of Pneumonitis in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors: a Multi-institutional Cohort Study https://jitc.bmj.com/content/10/6/e004670.long

Drs Jacob Sands and Jared Weiss discuss immunotherapy, including the importance of genomic testing, recent studies, new regimens, and the future of lung cancer treatment.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969534). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

Resources

Severe Immune-Related Adverse Events Are Common With Sequential PD-(L)1 Blockade and Osimertinib https://www.annalsofoncology.org/article/S0923-7534(19)31165-2/fulltext

Pembrolizumab Versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1606774

Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext

Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With PD-L1 of At Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-67362100228-2/fulltext

Cemiplimab-rwlc for First-Line Treatment of NSCLC With High PD-L1 Expression https://ascopost.com/issues/may-10-2021/cemiplimab-rwlc-for-first-line-treatment-of-nsclc-with-high-pd-l1-expression/

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1801005

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1810865

Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC https://www.nejm.org/doi/10.1056/NEJMoa1716948

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC https://www.jto.org/article/S1556-0864(21)02322-4/fulltext

First-Line Nivolumab plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/fulltext

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1910231

FDA Approves Nivolumab plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression ≥1%) https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1

Clinical and Genomic Characteristics of Pts With Durable Benefit From Immune Checkpoint Inhibitors (ICI) in Advanced Non-Small Cell Lung Cancer (aNSCLC). https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9048?af=R

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1809064

Durvalumab plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301) https://clinicaltrials.gov/ct2/show/NCT05060016

Drs Jacob Sands and Benjamin Levy discuss the management of lung cancer with neoadjuvant and adjuvant therapy and the potential impact of current clinical trials.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969535). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group https://ascopubs.org/doi/pdf/10.1200/JCO.2007.13.9030

ADAURA: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2027071

Osimertinib: Medscape Drugs & Diseases https://reference.medscape.com/drug/tagrisso-osimertinib-1000062

Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB–IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext

Atezolizumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/tecentriq-atezolizumab-1000098

Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext

Pembrolizumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/keytruda-pembrolizumab-999962

Pembrolizumab (Pembro) Versus Placebo for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Following Complete Resection and Adjuvant Chemotherapy (Chemo) When Indicated: Randomized, Triple-Blind, Phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Study https://oncologypro.esmo.org/meeting-resources/esmo-virtual-plenary-resources/pearls-keynote-091-pembrolizumab-pembro-versus-placebo-for-early-stage-non-small-cell-lung-cancer-nsclc-following-complete-resection-and-adjuvant-chemotherapy

Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2202170

Nivolumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/opdualag-nivolumab-relatlimab-4000249

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) https://ascopubs.org/doi/full/10.1200/JCO.21.02660

New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) https://clinicaltrials.gov/ct2/show/NCT04564157

Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer https://www.lungcancerresearchfoundation.org/research/lung-cancer-mutation-consortium/current-lcmc-study/

ALCHEMIST: Adjuvant Targeted Therapy or Immunotherapy for High-Risk Resected NSCLC https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.TPS9077

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study https://www.clinicaltrials.gov/ct2/show/NCT04267848

Drs Jacob Sands and Lauren Byers discuss the treatment options for patients diagnosed with small cell lung cancer and the future possibility of durable responses.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969536). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

Resources

FDA Approval Summary: Atezolizumab and Durvalumab in Combination With Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100557

First-line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-term Follow-up Results https://www.iaslc.org/iaslc-news/press-release/first-line-pembrolizumab-or-placebo-combined-etoposide-and-platinum-es

Lurbinectedin Prescribing Information https://pp.jazzpharma.com/pi/zepzelca.en.USPI.pdf

Lurbinectedin as Second-line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-label, Phase 2 Basket Trial https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(20)30068-1

Trilaciclib Prescribing Information https://www.g1therapeutics.com/file.cfm/69/docs/NDA_214200_COSELA_PI_20210212_US-2100006.pdf

Primary Analysis From the Phase 2 Study of Continuous Talazoparib (TALA) Plus Intermittent Low-Dose Temozolomide (TMZ) in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8517?af=R

Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319046/

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker https://clinicaltrials.gov/ct2/show/NCT04334941

The Role of Schlafen 11 (SLFN11) as a Predictive Biomarker for Targeting the DNA Damage Response https://www.nature.com/articles/s41416-020-01202-y

Molecular Subtypes of Small Cell Lung Cancer: A Synthesis of Human and Mouse Model Data https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538259/

Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC With Distinct Therapeutic Vulnerabilities https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30662-0

Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward https://www.nature.com/articles/nrc.2017.87

First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1809064

Durvalumab Plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext

Drs Jacob Sands and Narjust Florez discuss the importance of cultural humility in addressing bias and disparities in lung cancer, including screenings, patient care, hospice, and access to treatment.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969537). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

Resources

Assessing the Documentation of Social Determinants of Health for Lung Cancer Patients in Clinical Narratives https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35419333/

Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening

Race and Sex Differences in Patient Provider Communication and Awareness of Lung Cancer Screening in the Health Information National Trends Survey, 2013–2017 https://pubmed.ncbi.nlm.nih.gov/31054908/

Racial and Ethnic Disparities Among State Medicaid Programs for Breast Cancer Screening https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840870

The Tuskegee Timeline https://www.cdc.gov/tuskegee/timeline.htm

Are Racial and Ethnic Minorities Less Willing to Participate in Health Research? https://pubmed.ncbi.nlm.nih.gov/16318411/

Abstract 1641: Utilization of Palliative Therapies Among Hispanics With Stage IV Non-Small Cell Lung Cancer https://aacrjournals.org/cancerres/article/78/13_Supplement/1641/625802/Abstract-1641-Utilization-of-palliative-therapies

Early Palliative Care for Patients With Metastatic Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1000678

Medicaid Patients More Likely to Die at Home Without Hospice During the Pandemic Versus Before, Exacerbating Disparities With Commercially Insured Patients https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.6502

Assessment of Parking Fees at National Cancer Institute–Designated Cancer Treatment Centers https://jamanetwork.com/journals/jamaoncology/article-abstract/2768017

Cultural Humility: Essential Foundation for Clinical Researchers https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834043/

Drs Jacob Sands and Jared Weiss discuss subtypes; ongoing clinical trials; durable, ongoing responses to therapy; and the potential for using the word "cure" in the treatment of small cell lung cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Immunotherapy and Lung Cancer Treatment https://www.medscape.com/viewarticle/969534

Small Cell Lung Cancer (SCLC) https://emedicine.medscape.com/article/280104-overview

FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer

Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30068-1/fulltext

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer https://ascopubs.org/doi/10.1200/JCO.2006.06.5821

Study of Trilaciclib and Lurbinectidin https://clinicaltrials.gov/ct2/show/NCT05578326

PL02.03 Lurbinectedin/Doxorubicin Versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial https://www.jto.org/article/S1556-0864(21)02453-9/fulltext

Erythropoiesis-Stimulating Agents in Oncology: A Study-Level Meta-Analysis of Survival and Other Safety Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816662

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) https://clinicaltrials.gov/ct2/show/NCT05361395

Bispecific T-Cell Engager (BiTE) Antibodies https://reference.medscape.com/drugs/bispecific-t-cell-engager-bite-antibodies

Drs Jacob Sands and Julia Rotow discuss genomic testing, treatment options, and clinical trials for young adults who do not qualify for lung cancer screening.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984258). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Lung Cancer https://www.medscape.com/resource/lungcancer

Lung Cancer in Patients Under the Age of 40 Years https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687453/

Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States https://jamanetwork.com/journals/jamaoncology/article-abstract/2773380

What Are the Risks and Benefits of Lung Cancer Screening? https://www.medscape.com/viewarticle/969532

Biomarker Tissue Journey Among Patients With Untreated Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network https://pubmed.ncbi.nlm.nih.gov/35313244/

Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States https://pubmed.ncbi.nlm.nih.gov/35737912/

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer https://jamanetwork.com/journals/jamaoncology/fullarticle/2475482

Biology of Young Lung Cancer Study: The YOUNG LUNG Study https://clinicaltrials.gov/ct2/show/NCT05265429

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) https://www.clinical-lung-cancer.com/article/S1525-7304(22)00265-0/fulltext

Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations https://linkinghub.elsevier.com/retrieve/pii/S1525-1578(22)00080-0

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482929/

Immune Checkpoint Inhibitors for Patients With Advanced Lung Cancer and Oncogenic Driver Alterations: Results From the IMMUNOTARGET Registry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389252/

Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419340/

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(22)01068-6

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Induced Hepatic Failure in Lung Cancer Patients: A Study of Signal Mining and Analysis of the FDA Adverse Event Reporting System Database https://pubmed.ncbi.nlm.nih.gov/33768534/

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) https://www.clinicaltrials.gov/ct2/show/NCT03157128